<DOC>
	<DOCNO>NCT00148590</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety memantine add-on treatment prevention negative symptomatology patient acute exacerbation schizophrenia . Primary outcome parameter negative symptom 6 month</brief_summary>
	<brief_title>Memantine Prevention Negative Symptomatology</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Diagnosis schizophrenia ( DSMIV ) Age 18 40 Exacerbation acute schizophrenic episode ( PANSS positive score &gt; 20 ) At least one previous schizophrenic episode Informed consent Subjects must consider investigator compliant Subjects must educational level degree understand meaningfully communicate investigator Axis I disorder schizophrenia within 12 month , e.g . schizoaffective disorder Severe negative symptomatology ( PANNS negative score &gt; 20 point ) Duration schizophrenia &gt; 5 year Dependency alcohol addictive drug within 6 month baseline evaluation Contraindication risperidone Significant neurological , cardiovascular , hepatic , renal , metabolic , medical disease clinically relevant abnormality laboratory test Prior ECTtreatment , metal implantation Female subject pregnancy breastfeed Female subject within childbearing year use adequate birth control Patients judge investigator serious suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Memantine</keyword>
	<keyword>Negative syndrome</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Glutamate</keyword>
</DOC>